Shengyu G. Zhou
Beijing Key Laboratory Of Key Technologies For Early Clinical Trial Evaluation Of Innovative Drugs For Major Diseases, Chinese Academy Of Medical Sciences & Peking Union Medical College
Beijing, China
Beijing, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 73 publications
Safety, efficacy, and pharmacokinetics of eratrectinib (VC004) in solid tumors with NTRK fusions: phase 1 results from a phase 1/2 study.
Journal: Experimental hematology & oncology
Published: December 23, 2025
Combination of immunotherapy-based systemic therapy and radiotherapy achieves durable response and favorable survival in recurrent head and neck cancer.
Journal: Therapeutic advances in medical oncology
Published: February 05, 2025
Clinical, immune cell, and genetic features predicting survival and long-term response to first-line chemo-immunotherapy treatment for non-small cell lung cancer.
Journal: Cancer immunology, immunotherapy : CII
Published: December 27, 2024
Telpegfilgrastim for chemotherapy-induced neutropenia in patients with non-small cell lung cancer: a multicentre, randomized, phase 3 study.
Journal: BMC cancer
Published: November 07, 2024
Deciphering the Prognostic Significance of MYD88 and CD79B Mutations in Diffuse Large B-Cell Lymphoma: Insights into Treatment Outcomes.
Journal: Targeted oncology
Published: March 15, 2024
Efficacy and safety of PD-1 monoclonal antibody plus rituximab in relapsed/refractory diffuse large B cell lymphoma patients.
Journal: European journal of haematology
Published: April 04, 2023
Development and validation of a novel risk stratification model and a survival rate calculator for diffuse large B-cell lymphoma in the rituximab era: a multi-institutional cohort study.
Journal: Annals of hematology
Published: February 03, 2023
MYD88L265P and MYD88other variants show different molecular characteristics and prognostic significance in diffuse large B-cell lymphoma.
Journal: Journal of cancer research and clinical oncology
Published: February 03, 2023
Genetic Profiling of Diffuse Large B-Cell Lymphoma: A Comparison Between Double-Expressor Lymphoma and Non-Double-Expressor Lymphoma.
Journal: Molecular diagnosis & therapy
Published: October 06, 2022
Clinical characteristics and treatment outcomes of Chinese diffuse large B-cell lymphoma patients in the era of rituximab (2005-2018).
Journal: Cancer pathogenesis and therapy
Published: July 07, 2022
Last Updated: 09/26/2026